Rocket Pharmaceuticals Faces Shareholder Class Action Lawsuit Amid Allegations of Misleading Investors

Strategic Insights -

Rocket Pharmaceuticals, a biotechnology company developing gene therapies for rare diseases, is at the center of a shareholder class action lawsuit following allegations that it misled investors about the safety and progress of its critical RP-A501 gene therapy trial for Danon disease. The lawsuit, filed in response to the FDA's clinical hold on the Phase 2 trial, alleges that the company provided materially false and misleading statements regarding the safety, efficacy, and clinical protocol of the trial, leading to artificially inflated stock prices and substantial losses for investors.

Key Takeaways:

  • The lawsuit, styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.), claims that Rocket Pharmaceuticals misled investors about the safety and progress of its RP-A501 gene therapy trial for Danon disease.
  • The company allegedly failed to disclose significant protocol changes and known risks of Serious Adverse Events (SAEs), including patient deaths, to investors.
  • The FDA placed a clinical hold on the trial on May 27, 2025, after a patient's SAE and subsequent death, leading to a 62% decline in the company's stock price.
  • The investigation by Hagens Berman focuses on whether Rocket Pharmaceuticals provided materially false and misleading statements regarding the trial's safety, efficacy, and clinical protocol.
  • The class action complaint alleges that the company's statements created an artificially inflated stock price, and investors suffered heavy losses once the undisclosed risks and protocol changes became public.
  • The deadline to seek lead plaintiff status is August 11, 2025.
  • The lawsuit also highlights Hagens Berman's experience in corporate accountability and the firm's track record of securing significant recoveries for investors and whistleblowers.

Statistics:

  • 62% decline in Rocket Pharmaceuticals' stock price on May 27, 2025, following the FDA's clinical hold on the Phase 2 trial
  • 75% decline in the company's stock price from its February 27, 2025, closing price
  • $2.9 billion in recoveries secured by Hagens Berman in the area of corporate accountability
  • Up to 30% reward for whistleblowers who provide original information leading to a successful SEC recovery

Sources:

  • Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.)
  • Hagens Berman LLP press release, "Investigation: Rocket Pharmaceuticals (RCKT) Securities Class Action Lawsuit"
  • GlobeNewswire, "Rocket Pharmaceuticals Securities Class Action Lawsuit"